Biology of Blood and Marrow Transplantation
Volume 12, Issue 5 , Pages 573-584 , May 2006

Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen

Received 23 November 2005 ,Accepted 17 December 2005.

References 

  1. Deeg HJ , Storer B , Slattery JT , et al.   Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome . Blood . 2002;100:1201–1207
  2. de Lima M , Couriel D , Thall PF , et al.   Once-daily intravenous busulfan and fludarabine (clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS) . Blood . 2004;104:857–864
  3. Guardiola P , Runde V , Bacigalupo A , et al.   Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes . Blood . 2002;99:4370–4378
  4. Nevill TJ , Fung HC , Shepherd JD , et al.   Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation . Blood . 1998;92:1910–1917
  5. Sierra J , Pérez WS , Rozman C , et al.   Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia . Blood . 2002;100:1997–2004
  6. Jurado M , Deeg HJ , Storer B , et al.   Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality . Biol Blood Marrow Transplant . 2002;8:161–169
  7. Anderson JE , Appelbaum FR , Schoch G , et al.   Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology (a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors) . J Clin Oncol . 1996;14:220–226
  8. Clift RA , Buckner CD , Appelbaum FR , et al.   Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission (a randomized trial of two irradiation regimens) . Blood . 1990;76:1867–1871
  9. Deeg HJ , Spitzer TR , Cottler-Fox M , Cahill R , Pickle LW . Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis . Bone Marrow Transplant . 1991;7:193–198
  10. Martin PJ , Kernan NA . T-cell depletion for GVHD prevention in humans . In:  Ferrara JLM ,  Deeg HJ ,  Burakoff SJ editor. Graft-vs.-Host Disease . New York: Marcel Dekker, Inc; 1997;p. 615–637
  11. Bacigalupo A , Sormani MP , Lamparelli T , et al.   Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation . Haematologica . 2004;89:1238–1247
  12. Remberger M , Storer B , Ringden O , Anasetti C . Association between pretransplant Thymogloblulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors . Bone Marrow Transplant . 2002;29:391–397
  13. Remberger M , Mattsson J , Ringden O . Polyclonal anti-T-cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation . Pediatr Transplant . 2001;5:285–292
  14. Russell JA , Tran HT , Quinlan D , et al.   Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation (study of pharmacokinetics and early clinical outcomes) . Biol Blood Marrow Transplant . 2002;8:468–476
  15. Greenberg P , Cox C , LeBeau MM , et al.   International scoring system for evaluating prognosis in myelodysplastic syndromes . [erratum appears in Blood 1998;91:1100] Blood . 1997;89:2079–2088
  16. Slattery JT , Clift RA , Buckner CD , et al.   Marrow transplantation for chronic myeloid leukemia (the influence of plasma busulfan levels on the outcome of transplantation) . Blood . 1997;89:3055–3060
  17. Slattery JT , Risler LJ . Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation . Ther Drug Monit . 1998;20:543–549
  18. McCaul KG , Nevill TJ , Barnett MJ , et al.   Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin . J Hematother Stem Cell Res . 2000;9:367–374
  19. Deeg HJ , Amylon MD , Harris RE , et al.   Marrow transplants from unrelated donors for patients with aplastic anemia (minimum effective dose of total body irradiation) . Biol Blood Marrow Transplant . 2001;7:208–215
  20. Przepiorka D , Weisdorf D , Martin P , et al.   1994 Consensus conference on acute GVHD grading . Bone Marrow Transplant . 1995;15:825–828
  21. Petersdorf EW , Longton GM , Anasetti C , et al.   Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors . Blood . 1997;89:1818–1823
  22. Durnam DM , Anders KR , Fisher L , O’Quigley JO , Bryant EM , Thomas ED . Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay . Blood . 1989;74:2220–2226
  23. Shulman HM , Wells D , Gooley T , Myerson D , Bryant E , Loken MR . The biologic significance of rare peripheral blasts after hematopoietic cell transplantation is predicted by multidimensional flow cytometry . Am J Clin Pathol . 1999;112:513–523
  24. Scharf SJ , Smith AG , Hansen JA , McFarland C , Erlich HA . Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers . Blood . 1995;85:1954–1963
  25. Sievers EL , Lange BJ , Buckley JD , et al.   Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry . J Natl Cancer Inst . 1996;88:1483–1488
  26. Boeckh M , Nichols WG , Papanicolaou G , Rubin R , Wingard JR , Zaia J . Cytomegalovirus in hematopoietic stem cell transplant recipients (current status, known challenges, and future strategies) . Biol Blood Marrow Transplant . 2003;9:543–558
  27. Crippa F , Holmberg L , Carter RA , et al.   Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation . Biol Blood Marrow Transplant . 2002;8:281–289
  28. Boeckh M , Stevens-Ayers T , Bowden RA . Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation . J Infect Dis . 1996;174:907–912
  29. Carpenter PA , Appelbaum FR , Corey L , et al.   A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease . Blood . 2002;99:2712–2719
  30. Gooley TA , Leisenring W , Crowley J , Storer BE . Estimation of failure probabilities in the presence of competing risks (new representations of old estimators) . Stat Med . 1999;18:695–706
  31. Regan JF , Lyonnais C , Campbell K , Smith LV , Buelow R . Total and active Thymoglobulin levels (effects of dose and sensitization on serum concentrations) . Transpl Immunol . 2001;9:29–36
  32. Sorror ML , Maris MB , Storer B , et al.   Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning (influence of pretransplant comorbidities) . Blood . 2004;104:961–968
  33. Sorror ML , Maris MB , Storb R , et al.   Hematopoietic cell transplantation (HCT)-specific comorbidity index (a new tool for risk assessment before allogeneic HCT) . Blood . 2005;106:2912–2919
  34. Martin P , Nash R , Sanders J , et al.   Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation . Bone Marrow Transplant . 1998;21:273–279
  35. Cutler C , Giri S , Jeyapalan S , Paniagua D , Viswanathan A , Antin JH . Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation (a meta-analysis) . J Clin Oncol . 2001;19:3685–3691
  36. Remberger M , Svahn BM , Mattsson J , Ringden O . Dose study of Thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation . Transplantation . 2004;78:122–127
  37. Bacigalupo A , Lamparelli T , Bruzzi P , et al.   Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors (2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)) . Blood . 2001;98:2942–2947
  38. Bornhäuser M , Storer B , Slattery JT , et al.   Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells . Blood . 2003;102:820–826
  39. Guardiola P , Anderson JE , Bandini G , et al.   Allogeneic stem cell transplantation for agnogenic myeloid metaplasia (a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study) . Blood . 1999;93:2831–2838
  40. Dupriez B , Morel P , Demory JL , et al.   Prognostic factors in agnogenic myeloid metaplasia (a report on 195 cases with a new scoring system) . Blood . 1996;88:1013–1018

PII: S1083-8791(05)01417-5

doi: 10.1016/j.bbmt.2005.12.036

Biology of Blood and Marrow Transplantation
Volume 12, Issue 5 , Pages 573-584 , May 2006

Article Tools

* Image Usage & Resolution